{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:43Z","timestamp":1785551803954,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T00:00:00Z","timestamp":1313712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00228-011-1106-4","type":"journal-article","created":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T08:56:09Z","timestamp":1313657769000},"page":"207-211","source":"Crossref","is-referenced-by-count":21,"title":["Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects"],"prefix":"10.1007","volume":"68","author":[{"given":"Susan E.","family":"Shoaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Mallikaarjun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bricmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,19]]},"reference":[{"issue":"3","key":"1106_CR1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287(3):860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"1106_CR2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.ph.58.030196.003155","volume":"58","author":"LS King","year":"1996","unstructured":"King LS, Agre P (1996) Pathophysiology of the aquaporin water channels. Annu Rev Physiol 58:619\u2013648. doi: 10.1146\/annurev.ph.58.030196.003155","journal-title":"Annu Rev Physiol"},{"issue":"12","key":"1106_CR3","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","volume":"47","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S (2007) Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 47(12):1498\u20131507. doi: 10.1177\/0091270007307877","journal-title":"J Clin Pharmacol"},{"key":"1106_CR4","unstructured":"Otsuka Pharmaceutical (2009) Samsca\u00ae (tolvaptan): EU summary of product characteristics. Otsuka Pharmaceutical, Uxbridge"},{"issue":"5","key":"1106_CR5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.fjc.0000180899.24865.b6","volume":"46","author":"PJ Hauptman","year":"2005","unstructured":"Hauptman PJ, Zimmer C, Udelson J, Shoaf SE, Mallikaarjun S, Bramer SL, Orlandi C (2005) Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 46(5):609\u2013614","journal-title":"J Cardiovasc Pharmacol"},{"key":"1106_CR6","first-page":"762","volume":"51","author":"SE Shoaf","year":"2010","unstructured":"Shoaf SE, Ohzone Y, Ninomiya SI, Furukawa M, Bricmont P, Kashiyama E, Mallikaarjun S (2010) In vitro P-Glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 51:762\u2013769","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1106_CR7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MNH.0b013e3283436f14","volume":"20","author":"EA Elhassan","year":"2011","unstructured":"Elhassan EA, Schrier RW (2011) Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens 20(2):161\u2013168. doi: 10.1097\/MNH.0b013e3283436f14","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"1106_CR8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CRD.0b013e3181f5b3b7","volume":"18","author":"N Ferguson-Myrthil","year":"2010","unstructured":"Ferguson-Myrthil N (2010) Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan. Cardiol Rev 18(6):313\u2013321. doi: 10.1097\/CRD.0b013e3181f5b3b7","journal-title":"Cardiol Rev"},{"issue":"4","key":"1106_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/fca.10.22","volume":"6","author":"EJ Hoorn","year":"2010","unstructured":"Hoorn EJ, Zietse R (2010) Vasopressin-receptor antagonists. Future Cardiol 6(4):523\u2013534. doi: 10.2217\/fca.10.22","journal-title":"Future Cardiol"},{"issue":"6","key":"1106_CR10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1517\/14656566.2011.567267","volume":"12","author":"A Ambrosy","year":"2011","unstructured":"Ambrosy A, Goldsmith SR, Gheorghiade M (2011) Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother 12(6):961\u2013976. doi: 10.1517\/14656566.2011.567267","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1106_CR11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10741-009-9152-z","volume":"15","author":"NS Rehsia","year":"2010","unstructured":"Rehsia NS, Dhalla NS (2010) Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. Heart Fail Rev 15(1):85\u2013101. doi: 10.1007\/s10741-009-9152-z","journal-title":"Heart Fail Rev"},{"issue":"4","key":"1106_CR12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000326902","volume":"34","author":"E Meijer","year":"2011","unstructured":"Meijer E, Boertien WE, Zietse R, Gansevoort RT (2011) Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 34(4):235\u2013244. doi: 10.1159\/000326902","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"1106_CR13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS (2011) Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3\u20134 Study. Am J Kidney Dis 57(5):692\u2013699. doi: 10.1053\/j.ajkd.2010.11.029","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1106_CR14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0025-7125(05)70535-6","volume":"81","author":"LF Fried","year":"1997","unstructured":"Fried LF, Palevsky PM (1997) Hyponatremia and hypernatremia. Med Clin North Am 81(3):585\u2013609","journal-title":"Med Clin North Am"},{"issue":"3","key":"1106_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/17425255.2011.553189","volume":"7","author":"MJ Hanley","year":"2011","unstructured":"Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ (2011) The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7(3):267\u2013286. doi: 10.1517\/17425255.2011.553189","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"18","key":"1106_CR16","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2165\/11585250-000000000-00000","volume":"70","author":"K Seden","year":"2010","unstructured":"Seden K, Dickinson L, Khoo S, Back D (2010) Grapefruit-drug interactions. Drugs 70(18):2373\u20132407. doi: 10.2165\/11585250-000000000-00000","journal-title":"Drugs"},{"key":"1106_CR17","unstructured":"U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) (2002) Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies, pp 1-12. http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126833.pdf Accessed 15 July 2011"},{"key":"1106_CR18","unstructured":"Jusko W (1992) Guidelines for collection and analysis of pharmacokinetic data. In: Evans W, Juskko W, Schentag J (eds) Applied pharmocokinetics: principals of therapeutic drug monitoring, 3rd edn. Applied Therapeutics, Inc., pp 1\u201343"},{"issue":"2","key":"1106_CR19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199733020-00003","volume":"33","author":"B Ameer","year":"1997","unstructured":"Ameer B, Weintraub RA (1997) Drug interactions with grapefruit juice. Clin Pharmacokinet 33(2):103\u2013121","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"1106_CR20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2165\/00003088-200342130-00001","volume":"42","author":"RZ Harris","year":"2003","unstructured":"Harris RZ, Jang GR, Tsunoda S (2003) Dietary effects on drug metabolism and transport. Clin Pharmacokinet 42(13):1071\u20131088","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1106_CR21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11095-008-9771-4","volume":"26","author":"Y Shirasaka","year":"2009","unstructured":"Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I (2009) Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 26(3):560\u2013567. doi: 10.1007\/s11095-008-9771-4","journal-title":"Pharm Res"},{"issue":"1","key":"1106_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.109.159756","volume":"332","author":"Y Shirasaka","year":"2010","unstructured":"Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I (2010) Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 332(1):181\u2013189. doi: 10.1124\/jpet.109.159756","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1106_CR23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P, Zimmer CA (2007) Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 50(2):213\u2013222. doi: 10.1097\/FJC.0b013e318074f934","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1106-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1106-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T22:34:07Z","timestamp":1741473247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1106-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,19]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1106-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,19]]}}}